Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Lipids reducing

The permeability of solutes across lipid bilayers is a product of the partition coefficient and the transverse diffusion coefficient [30]. Bilayer polymerization can alter solute diffusion by modifying either or both of these processes. In order to examine the effect of polymerization on bilayer permeability a nonionic solute of moderate permeability, [3H-glucose], was encapsulated in the vesicles prior to polymerization, removed from the exterior after polymerization, and its permeation across the bilayer was measured periodically [31]. Quantitative measurements of the 3H-glucose leakage revealed that the formation of linear polymer chains from methacryloyl lipids reduced the permeability coefficient to 0.3 to 0.5 of that of the unpolymerized lipid vesicles. A larger reduction (two orders of magnitude) was only found when crosslinked polymer networks were formed [31]. [Pg.60]

Small volume of yellow bile, low value of acid phosphatase, muscle protein normal, water content down to fed values, liver lipid reduced -recovery almost complete. [Pg.214]

Samples containing metamizol, EDTA, gentisinic acid or to which lipid reducers have been added (Liposol), cannot be measured by the Seralyzer. These substances interfere with the measurement. [Pg.447]

Emulsifiers are necessary to allow water and lipids to combine. A surfactant is an amphiphilic molecule that has affinities for fats as well as water and that can be incorporated into lamellar lipid structures (e.g. cell walls). Surfactants increase the fluidity of the lipid structures by partitioning into the lipid membranes, as their lateral interactions with the membrane-forming lipids reduce the force of their attractive interaction. The mobility of the membrane lipids increases considerably in a similar manner to when a liquid crystal is converted into a gel. Finally, lipids can be seen to micellize or simply dissolve. Membranes lose their relative impermeability. See Figure 5.16. [Pg.41]

PIMs, LM, LAM, and AM appear to be structurally (Figure 2) and, hence, biosynthetically related to each other, in that LM appears to be mannosylated PIM, LAM appears to be arabinosylated LM, and AM appears to be LAM minus the lipid anchor. Thus, the fully mature Ai. tuberculosis LAM is most easily viewed as composite of four regions a lipidated reducing end (in essence a phosphatidylinositol (PI) anchor), a mannan core (which together with the anchor makes up the LM region), and the arabinofiiran with its mannose (Man) caps, and a... [Pg.383]

Lovastatin is absorbed to the extent of 30% and undergoes an extensive first-pass hepatic extraction. Lovastatin is converted to the active B hydroxy acid form in the liver. Other metabolites include the 6, hydroxy derivative and two unidentified compounds. About 80% of lovastatin is excreted primarily in feces, about 10% in urine. Concomitant administration with cholestyramine or colestipol may enhance lipid-reducing effects but may decrease bioavailability... [Pg.398]

Thieno[2,3- )]- and -[3,2-Z ]thiophene-2-carboxylic acids and their benzo[Z ]annu-lated analogues were synthesized and their lipid-reducing properties were investigated (78APS368). A number of hydrazides and sulfonamides of the thienothiophene series were patented as pesticides (8 5EUP146263, 92EUP483647). [Pg.181]

Ileal bypass (see Section VB2) performed for hypercholesterolemic patients (269) increased cholesterol elimination in the study by Moore et al. (156) about fivefold as bile acids and threefold as neutral steroids according to the isotopic balance technique. Serum cholesterol reduction was about 40 %. In our own series, consisting of patients with familial hypercholesterolemia only, similar results have been obtained by the chemical balance technique except that elimination of cholesterol increased solely as bile acids (11,63,127). The fecal bile salt loss was associated with a 35 % fall in the serum cholesterol level, a severalfold increased cholesterol synthesis, impaired micellar solubilization of digested lipids, reduced intestinal bile salt concentrations, and decreased cholesterol level in the intestinal contents. The last suggests that biliary secretion of cholesterol was markedly decreased so that, despite impaired cholesterol reabsorption, fecal neutral steroid excretion remained quite unchanged. An increased fecal bile salt loss associated with stimulated cholesterol production has been reported also by Grundy et al. (94). [Pg.236]

In the particular case of foodstuffs, problems may arise from the presence of other food components, such as some lipids, reducing sugars, and phenolic compounds, which may form derivatives resulting in altered quantification. For problem samples, the use of internal standards added prior to hydrolysis is highly recommended. [Pg.3944]

Qualitative and quantitative changes in grain carbohydrates, proteins, lipids Reduced grain germination Mycotoxins... [Pg.111]

The emptying of the stomach contents into the duodenum is controlled by osmotic sensors in the duodenum. In addition, the presence of excess lipid reduces the emptying rate. [Pg.160]

As mentioned earlier, saturated fatty acids (SFA) of foods are regarded as the cause of a high-risk pattern of blood lipoproteins octadecanoic (stearic, Cig) acid and tetradecanoic (myristic, C14) acid and also all trans acids are considered to be the most damaging. With increasing consumption of SFA, blood levels of cholesterol and LDL are raised. Conversely, the polyunsaturated fatty acids (PUFA) are judged to be beneficial, although the various families of PUFA differ in their effects the n-6 PUFA (which occur mainly in plant lipids) reduce the blood concentration of LDL, and the n-3 PUFA (from fish lipids) reduce VLDL. It is considered desirable to have a balance in the diet of n-6 to n-3 PUFA the recommended maximum ratio is 4 1. In between the SFA and PUFA are the monounsaturated fatty acids (MUFA), such as octadecenoic (oleic, 18 1) acid, which are regarded as neutral or possibly beneficial to blood lipoproteins. [Pg.619]

Pasternak RC, Brown LE, Stone PH, et al. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and normal cholesterol eye s. Arm Inter Med 1996 125 259-540. [Pg.222]

At CMCs of 2-5 X 10 M, the mannosylerythritol lipids reduced the surface tension of water and the interfadal tension between water and n-tetradecane to about 28 and 2 mN/m, respectively [60]. To examine the emulsifying activity (o/w emulsions, optical density measurements at 620 nm) of MEL-A and B produced from n-octadecane, various oils were used [55]. They showed much higher activity for soybean oil than did Tween 80 at 50 mg/L. With respect to -tetradecane, the activity of MEL-A was higher than that of Tween 80 whereas that of MEL-B was similar. MEL-SY16 from C. antarctica sp SY16 lowered the water surface tension to 29 mN/m at CMC of 1.5 X 10 M (10 mg/L) the minimum interfacial tension was 0.1 mN/m against kerosene [57]. Evaluating the properties of mannosylerythritol lipids from Pseudozyma Candida ATCC 20509, it was observed that the culture broth decreased the water surface tension to 35 mN/m [56]. [Pg.293]

Recent literature does not point to side effects of nicotinic acid and its derivatives other than those which were reviewed in SED VIII (p. 936). The field has been reviewed by Parsons (26 ), who has stressed the need for a major study to determine the long-term effects of nicotinic acid as compared with other lipid-reducing agents. One of the few long-term studies recently reported, that of Zbllner et al. (27 ) is a follow-up on 37 patients who had been treated for hypercholesterolaemia with nicotinyl alcohol for between 6 and 8 years. Those who had taken more than 0.9 g daily still had a lower serum cholesterol than at the beginning of treatment, and there was no evidence of long-term adverse effects. [Pg.333]

Parsons Jr., W. B. (1975) Nicotinic acid in hyperlipidemia clinical guidelines in the use of a broad spectrum lipid reducing agent. Clin. Med., 82, 19. [Pg.335]


See other pages where Lipids reducing is mentioned: [Pg.118]    [Pg.71]    [Pg.167]    [Pg.6]    [Pg.254]    [Pg.477]    [Pg.201]    [Pg.349]    [Pg.350]    [Pg.687]    [Pg.574]    [Pg.249]    [Pg.67]    [Pg.62]    [Pg.428]    [Pg.457]    [Pg.129]    [Pg.7]    [Pg.284]    [Pg.800]    [Pg.359]    [Pg.301]    [Pg.52]    [Pg.26]    [Pg.225]    [Pg.168]    [Pg.75]    [Pg.74]    [Pg.129]   
See also in sourсe #XX -- [ Pg.21 ]




SEARCH



Lipid metabolism reducing

Serum lipid concentrations, reducing

Serum lipid reducing agents

© 2024 chempedia.info